Our first product to serve these markets is the AURORA Tissue Imaging system, followed by the TumorMAP system for intraoperative prostate margin assessment.

The company is currently engaged in clinic training of the AURORAVision AI-Algorithm for use in TURBT, funded in part by a NIH/NCI grant. The company plans for FDA approval of AURORA by the end of 2024.

We are also engaged in a research study for algorithm development and training in radical prostatectomy surgery at AdventHealth, Orlando, Florida.